Big Win for Addiction Recovery: Congress Renews Funding for Treatment Programs Through 2030

The National Institute on Drug Abuse (NIDA) is celebrating a major milestone as overdose deaths dropped nearly 17% from July 2023 to July 2024, falling from over 113,000 to 94,000 deaths. This marks the first sustained downturn in fatal overdoses in years, coinciding with NIDA's 50th anniversary and renewed federal commitment to addiction treatment and recovery programs.

What's Driving the Drop in Overdose Deaths?

While researchers are still investigating the exact factors behind this encouraging trend, the decline represents a significant shift in the overdose crisis that has plagued communities nationwide. However, the improvement isn't uniform across all populations—Black and American Indian/Alaskan Native communities continue to experience increased overdose rates, highlighting persistent health disparities.

Dr. Nora Volkow, NIDA's director, emphasized that "94,000 people dying of overdose in a year is still 94,000 too many," underscoring the ongoing urgency of addiction treatment and prevention efforts.

Ways to Expand Addiction Recovery Through Four Federal Priority Areas

NIDA has identified four priority areas for 2025 that will receive significant research funding and policy attention. These initiatives represent a comprehensive approach to tackling substance abuse from multiple angles.

• Prevention Programs: Early intervention strategies targeting prenatal drug exposure, adverse childhood experiences, and adolescent substance experimentation, with some studies showing intergenerational benefits for families
• Overdose Prevention Technology: Development of wearable devices that auto-inject naloxone during overdoses and new compounds to reverse methamphetamine overdoses using monoclonal antibodies
• Treatment Access Expansion: Addressing the gap where only 14.6% of people with substance use disorder (SUD) received treatment in 2023, with particular focus on methadone accessibility through pharmacies
• Justice System Integration: Implementing medication-assisted treatment in jails and prisons, which research shows reduces fatal overdose risk by nearly 32% after release

Why Treatment Access Remains a Critical Challenge?

Despite proven treatments being available, access remains severely limited. Only 18% of people with opioid use disorder (OUD) received medication in 2023, largely due to stigma and inadequate insurance coverage for addiction treatment.

The justice system presents both a challenge and opportunity. Research in correctional settings demonstrates that providing access to all three Food and Drug Administration (FDA)-approved medications for opioid use disorder during incarceration reduces both overdose deaths and recidivism by approximately 32%.

Naloxone distribution has emerged as a major success story, with recipients of Substance Abuse and Mental Health Services Administration (SAMHSA) grants alone reporting more than 92,000 overdose reversals in the year ending March 2023. This likely represents just a fraction of total lives saved through naloxone access programs.

Looking ahead, contingency management—providing incentives for treatment participation and negative drug tests—shows promise as the most effective treatment for methamphetamine and cocaine addictions. Demonstration projects in California, Washington, Montana, and Delaware are testing higher incentive levels to overcome previous regulatory barriers.